Johnson & Johnson (JNJ) exhibits 67.9% gross margins and 25.5% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 18.5x enterprise multiple and 7.2% implied options volatility.
Sustained 67.9% gross profitability converts into 34.7% operating margin and 25.5% ROIC, outpacing sector cost of capital.
ROIC: 25.5% // GM: 67.9%YoY revenue trajectory of +6.0% paired with 2.97% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +6.0% // FCF YLD: 2.97%Altman Z-Score of 5.59 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.59 // F-SCORE: 8/9Trading at 24.7x trailing P/E (23.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.7x // EV/EBITDA: 18.5xOptions market prices a ±7.2% implied move with a 0.73 put/call ratio around $270.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.73Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 28.5% net margins.
NET MARGIN: 28.5% // D/E: 0.48x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for JNJ & activate live FRED threshold breach alerts.